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WATER-SOLUBLE DERIVATIVES OF 
CAMPTOTHECIN/HOMOCAMPTOTHECIN 
This application claims the bene?t of US. Provisional 
Patent Application No. 60/122,621 ?led March 3, 1999. 
This invention Was made With US. Government support 
under Grant Number NIH CA 63653 aWarded by the 
National Institutes of Health. In addition to its existing 
rights, the United States of America may have additional 
rights to this invention under the above grant. 
TECHNICAL FIELD 
The present invention relates to Water-soluble camptoth 
ecin and homocamptothecin compounds. More particularly, 
the invention relates to C-7 substituted camptothecin deriva 
tives prepared by C-7 haloalkylation, Hydroalkylation and 
aminoalkylation of camptothecin or its C-12 substituted 
7-membered E-ring analog 5-ethyl-5-hydroxy -1,4,5,13 
tetrahydro-3H,15H-oxepino[3‘,4‘:6,7]indoliZino-[1,2-b] 
quinoline-3,15-dione (homocamptothecin) derivatives pre 
pared by C-12 haloalkylation, hydroalkylation and 
aminoalkylation of homocamptothecin to form Water 
soluble camptothecin/homocamptothecin compounds. 
BACKGROUND OF THE INVENTION 
Camptothecin, a plant alkaloid isolated from trees indig 
enous to China, and analogs thereof such as 
9-aminocamptothecin, 9-nitrocamptothecin, 
10-hydroxycamptothecin, 10,11 
methylenedioxycamptothecin, 9-nitro- 10,1 1 - 
methylenedioxycamptothecin, 9-chloro- 1 0, 11 - 
methylenedioxycamptothecin, 9-amino-10,11 
methylenedioxycamptothecin, 7-ethyl- 10 
hydroxycamptothecin (SN-38), topotecan, DX-8 951, 
Lurtotecan (GI147221C), and other analogs (collectively 
referred to herein as camptothecin drugs) are presently under 
study WorldWide in research laboratories and cancer clinics. 
In lab tests and in clinical trials, these camptothecin drugs 
have aroused considerable interest as a result of their ability 
to halt the groWth of a Wide range of human tumors. For 
example, these drugs exhibit unprecedented high levels of 
antitumor activities against human colon cancer 
[Giovanella, et al. Science 246: 1046—1048 (Washington, 
DC.) (1989)]. Camptothecin drugs have also been shoWn to 
be effective against other experimental cancer types such as 
lung, breast, and malignant melanoma. 
Camptothecin drugs are thought to inhibit the prolifera 
tion of cancer cells by interfering With the breakage/reunion 
reaction of the enZyme topoisomerase I, a nuclear enZyme 
implicated in DNA replication and RNA transcription. A 
camptothecin drug stabiliZes and forms a reversible enZyme 
camptothecin-DNA ternary complex, designated the cleav 
age complex. The formation of the cleavable complex 
speci?cally prevents the reunion step of the breakage/union 
cycle of the topoisomerase reaction. Topoisomerase I inhibi 
tors are also knoWn to be useful in the treatment of HIV. 
Camptothecin and homocamptothecin both contain ?ve 
membered ring systems as shoWn beloW. 
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For both camptothecin (top structure) and homocamptoth 
ecin (bottom structure), Z=hydrogen. Unfortunately, 
camptothecin/homocamptothecin and many structurally 
related camptothecin analogs/derivatives are Water 
insoluble. This Water insolubility makes administration of 
camptothecin drugs dif?cult. In an effort to address this 
problem a number of synthetic efforts have been directed to 
derivatiZing the A-ring and/or B-ring to improve Water 
solubility While maintaining cytotoxic activity. 
To date, some Water-soluble camptothecin derivatives 
have been prepared by derivatiZing the A and B rings and by 
opening the lactone E-ring. See, for example, U.S. Pat. Nos. 
5,646,159, 5,559,235, 5,670,500, 5,663,177, 5,677,286, and 
5,734,056. US. Pat. No. 5,646,159 discloses Water-soluble 
pro-drug type camptothecin compounds, in Which the 
20-position hydroxyl group is esteri?ed. Enzymes present 
Within the body can break the ester bond after injection to 
form the parent camptothecin compound. 
U.S. Pat. No. 5,559,235 discloses Water-soluble camp 
tothecin compounds, in Which the Aring has 10,11-ethylene 
or methylenedioxy rings and substituents at C-7. U.S. Pat. 
No. 5,670,500 discloses Water-soluble camptothecin drugs, 
in Which the A ring is connected to the substituted furan 
ring. U.S. Pat. No. 5,663,177 discloses Water-soluble camp 
tothecin analogs, in Which the A- and B rings are connected 
With a heterocyclic ring containing nitrogen. US. Pat. No. 
5,677,286 discloses Water-soluble camptothecin analogs in 
Which the A ring has non-ionic sugar moieties, Which 
increase the Water solubility. US. Pat. No. 5,734,056 dis 
closes the process for the preparation of 10-hydroxy-9-alkyl 
analogs of camptothecin. 
Aneed continues to exist for the development of neW and 
better camptothecin and homocamptothecin compounds 
having still higher antitumor activity and still more 
improved Water-solubility While exhibiting loW levels of 
toxicity. 
SUMMARY OF THE INVENTION 
Accordingly, it is a primary object of the present invention 
to provide neW camptothecin and homocamptothecin com 
pounds including analogs and derivatives displaying cyto 
toxic activity and improved Water-solubility for ease and 
ef?ciency of administration/delivery. 
Still another object of the present invention is to provide 
neW camptothecin and homocamptothecin drugs including 
analogs and derivatives, processes for preparing said ana 
logs and derivatives and formulations containing such ana 
logs and derivatives. 
Yet another object of this invention is the provision of neW 
camptothecin and homocamptothecin drugs including 
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derivatives possessing high anti-tumor activity and Water 
solubility and minimal toxicity. 
Other objects and advantages of the present invention Will 
become apparent as the description thereof proceeds. In 
satisfaction of the foregoing objects and advantages, there is 
provided by this invention camptothecin and homocamp 
tothecin drugs having the structures shoWn beloW. 
The compounds of the present invention are prepared by 
substitution of the 7-position of camptothecins or 
12-position of homocamptothecins to form Water-soluble 
compounds containing an aminoalkyl moiety. The ami 
noalkyl moiety may incorporate either an unbranched or 
branched alkyl chain. The homocamptothecin structure can 
be readily prepared starting from camptothecin according to 
a published method (Bigg et al., Biorganic and Medicinal 
Chemistry Letters (1997) 17 2235—2238) or can be prepared 
folloWing derivitaZation at position 7. Generally, the camp 
tothecins serving as starting materials are suspended in 
organic solvents or Water, stirred and cooled. To the mixture 
is added the folloWing compounds Which give equivalent 
structure to Z: halo alcohols, amino alcohols, amino 
aldehydes, halo aldehydes, halo ketones, aZido alcohols, 
aZido aldehydes, sulfuric acid, iron sulfate and oxidiZing 
reagents such as peracids and hydrogen peroxide. The 
mixture is then stirred to complete the reaction. Any pre 
cipitate Which forms is removed by ?ltration and the product 
is isolated after removal of the solvent. 
Z in the structure shoWn above is: 
A) CL2O NRlR2 Where 
(1) R1 is hydrogen, CL18 alkyl, C3_7 cycloalkyl, C3_7 
cycloalkyl-C1_18 alkyl, C2_18 alkenyl, hydroxy-C1_18 
alkyl, CL18 alkoxy-C1_18 alkyl and R2 is CL2O NR3R4 
Where: (a) R3 and R4 are independently, hydrogen, 
CL18 alkyl, C3_7 cycloalkyl, C3_7 cycloalkyl-C1_18 
alkyl, C2_18 alkenyl, hydroxy-CM8 alkyl, CL18 alkoxy 
C1_18 alkyl, 3—7 membered heterocyclic ring Which 
may contain a O, S or N group; (b) R3 is hydrogen and 
R4 is CL18 alkyl, C3_7 cycloalkyl, C3_7 cycloalkyl-C, 
alkyl, C2_18 alkenyl, hydroxy-C1_18 alkyl or CL18 
alkoxy-C1_18 alkyl, perhalo-C1_18 alkyl, C3_7 
cycloalkyl, C3_7 cycloalkyl-C M8 alkyl, C2_18 alkenyl, 
hydroxy-C1_18 alkyl, C1_18 alkoxy, CL18 all<oxy-C1_18 
alkyl; (c) R3 and R4 taken together With the nitrogen 
atom to Which they are attached form a saturated 
3—7-membered heterocyclic ring Which may contain a 
O, S or NR5 group, Where R5 is hydrogen, CL6 alkyl, 
perhalo-C1_6 alkyl, aryl, aryl substituted With one or 
more groups selected from the group consisting of CL6 
alkyl, halogen, nitro, amino, CL6 alkyl, CL6 alkoxy, 
C1_6 alkoxy-C1_6 
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alkyl and —COR6 Where R6 is hydrogen, CL6 alkyl, 
perhalo-C1_6 alkyl, CL6 alkoxy, aryl, and aryl substituted 
With one or more CL6 alkyl, perhalo-C1_6 alkyl, hydroxy 
CL6 alkyl, or CL6 alkoxy-C1_6 alkyl groups, 
(2) R1 is hydrogen, CL18 alkyl, C3_7 cycloalkyl, C3_7 
cycloalkyl-C1_18 alkyl, C2_18 alkenyl, hydroxy-C1_18 
alkyl, CL18 alkoxy-C1_18 alkyl, and R2 can be any one 
of the folloWing alkylamines or alkyl polyamines or a 
corresponding salt form: 
—C(NCH3)NH(CH2)4NH2 
(3) R1 is hydrogen, CL18 alkyl, C3_7 cycloalkyl, C3_7 
cycloalkyl-C1_18 alkyl, C2_18 alkenyl, hydroxy-C1_18 
alkyl, CL18 all<oxy-C1_18 alkyl, and R2 can be either 
CO(OCH2)nOR1O or CH2(OCH2)nOR1O Where n=1—2, 
000 and R10 is either hydrogen. CL1O alkyl, or aryl. 
(4) NR‘lR2 is guanidino group; and 
(5) R1 is hydrogen, C1_8 alkyl, C3_7 cycloalkyl, C3_7 
cycloall<yl-C1_8 alkyl, C2_8 alkenyl, hydroxy-C1_8 alkyl, 
CL8 alkoxy-C1_8 alkyl, R2 is CL8 alkyl-SiRnRlzR13 
Where R11, R12, and R13 are methyl or R11, R12, and R13 
are independently CL1O alkyl, C2_8 alkenyl, C2_8 alky 
nyl CL8 alkoxy, CL8 aminoalkyl, C1_8 hydroxyalkyl, 
and haloalkyl groups. 
B) C2_2O NRlR2 Where (a) R1 and R2 taken together With the 
nitrogen atom to Which they are attached form a saturated 
3—7-membered heterocyclic ring Which may contain a O, 
S or NR3 group, Where R3 is hydrogen, C1_6 alkyl, 
perhalo-C1_6 alkyl, aryl, aryl substituted With one or more 
groups selected from the group consisting of CL6 alkyl, 
halogen, nitro, amino, CL6 alkyl, CL6 alkoxy, CL6 
alkoxy-C1_6 alkyl and COR4 Where R4 is hydrogen, C1_6 
alkyl perhalo-C1_6 alkyl, C1_6 alkoxy, aryl, and aryl sub 
stituted With one or more CL6 alkyl, perhalo-C1_6 alkyl, 
hydroxy-C1_6 alkyl, or C1_6 alkoxy-C1_6 alkyl groups; 
C) C12_2O NRlR2 Where (1) R1 and R2 are independently, 
hydrogen, CL18 alkyl, C3_7 cycloalkyl, C3_7 cycloalkyl 
CL18 alkyl, C2_18 alkenyl, hydroxy-C1_18 alkyl, C1_18 
alkoxy-C1_18 alkyl or (2) R1 is hydrogen and R2 is C1_18 
alkyl, C3_7 cycloalkyl, C3_7 cycloalkyl-C1_18 alkyl, C2_18 
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Preferred aryl groups are phenyl and naphthyl. Suitable 
heterocyclic rings de?ned by a covalent association betWeen 
R3 and R4 and the nitrogen atom to Which they are attached 
include the folloWing: aZiridine, aZetidine, pyrolidine, 
piperidine, heXamethylenimine, imidaZolidine, 
pyraZolidine, isoXaZoline, piperaZine, methylpiperaZine, 
homopiperaZine, -methyl-homopiperaZine and thiaZolidine. 
The free amine of any of the compounds of the present 
invention may be converted to an acid addition salt by the 
addition of a pharmaceutically acceptable acid Well knoWn 
in the art to be suitable for this purpose. Suitable addition 
salts include, but are not limited to hydrochloride, sulfate, 
phosphate, diphosphate, hydrobromide, nitrate, acetate, 
malate, maleate, fumarate, tartrate, succinate, citrate, lactate, 
methanesulfonate, p-toluenesulfonate, palmoate, salicylate, 
stearate, quaternary ammonium, and tri?uoroacetate salts. 
The salts may be puri?ed by crystalliZation from a suitable 
solvent such as Water or ethanol. 
Advantageously, the novel compounds/drugs of the 
present invention exhibit a number of unique properties and 
characteristics Which When considered in combination 
clearly establish the superiority of these compounds for use 
in antitumor therapy and treatment. The novel compounds 
display good biological activity While also possessing favor 
able characteristics for active loading into liposomal particle 
drug delivery systems of the type disclosed and described in 
US. Pat. Nos. 5,316,771, 5,552,156 and 5,736,156 to Burke. 
In this document it is demonstrated that pre-made liposomes 
can be efficiently loaded With the novel compounds of this 
invention using pH gradients. 
In addition, the novel compounds/drugs display enhanced 
Water solubility. Accordingly, there is reduced membrane 
binding Which means that the compounds/drugs of the 
present invention tend to reside in the more aqueous inner 
compartments of the liposome aWay from the membrane 
components. As a result, the compounds/drugs are fully held 
in an environment Where they are protected from physi 
ological pH during delivery to the tumor site. As a 
consequence, the compounds/drugs remain more stable in 
their anti-tumor active lactone form and are thus more 
efficiently and effectively delivered to the site of cancer 
cells. There the compounds/drugs diffuse out of the lipo 
some and inhibit tumor groWth by inhibiting the DNA 
synthesis and reversibly fragmenting the DNA of the cancer 
cells. 
The claimed compounds/drugs With polyamine substitu 
tion include a linking-alkyl chain betWeen the nitrogen 
substituted group and the pyridine ring Which provide a 
number of advantages. 
An increase in the number of nitrogen atoms present in the 
C-7 substituent in camptothecins and the C-12 substituent in 
homocamptothecins increases the effective positive charge 
of the molecule, thereby giving the agent better solubility 
and alloWing the compounds to still interact With important 
cellular components such as membranes and the topoi 
somerase I enZyme. In addition, different lengths of alkyl 
linkage betWeen the nitrogen atoms produce different activi 
ties (for eXample the polyamine analogs BE-3-3-3, BE-3-7 
3, BE-4-4-4-4). 
The provision of substituents on the pyridine ring With 
more than I nitrogen atom (polyamine like structures) is also 
important for the folloWing reasons: 
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a. The stability of the lactone form (and anticancer 
activity as Well) increases in key biological matrices 
such as human blood. 
b. The utility of the polyamine analogs as single agents is 
enhanced for a variety of tumor types, due to the ability 
to combine such agents With other therapeutic modali 
ties. Previous studies have shoWn that the depletion of 
polyamine like structures produced by DFMO, MGBG, 
or other inhibitors of polyamine biosynthesis could 
modify the activity of other DNA-directed chemothera 
peutic agents, such as the chloroethylnitrosoureas; 
cisplatinum, and topoisomerase related agents such as 
4‘-(9-acrydinyl-amino) methanesulfon-M-anisidide 
(M-AMSA). Thus, the presence of polyamine-like 
structures could modulate the activities of other anti 
cancer drugs used in combination With the compounds/ 
drugs of the present invention. 
BRIEF DESCRIPTION OF THE DRAWINGS 
FIG. 1 is the ?uorescence emission spectra of 1 pM of 
7-(1-Aminoethyl)camptothecin (7AEC) in various solvents 
and suspensions such as phosphate buffered saline, ethanol, 
and phosphate buffered saline containing small unilamellar 
vesicles (SUVs) composed either of dimyristoylphosphati 
dylcholine (DMPC) or dimyristoylphosphatidlyglycerol 
(DMPG). Experiments Were conducted at 37° C. using 
exciting light of 370 nm. Note that in the presence of 
liposomes composed of either DMPC or DMPG the ?uo 
rescence emission spectra of 7AEC shifts to shorter 
Wavelength, indicative of drug interaction With the mem 
branes (lipid concentration 0.04M, )tex=370 nm, EX reso 
lution 4 nm, EM resolution 4 nm, Without EM polariZer, 
HV=810 V). 
FIG. 2 is the ?uorescence emission spectra of 4 pM of 
7-[N-(4-methyl-1-piperaZino) aminomethyl]-(20S) 
camptothecin (CT-17) in various solvents and suspensions 
such as phosphate buffered saline, ethanol, and phosphate 
buffered saline containing small unilamellar vesicles 
(SUVs) composed either of DMPC or DMPG. Experiments 
Were conducted at 37° C. using exciting light of 370 nm. 
Note that in the presence of liposomes composed of either 
DMPC or DMPG the ?uorescence emission spectra of 
CT-17 increases in intensity and shifts to shorter 
Wavelength, indicative of drug interaction With the mem 
branes (lipid concentration 0.04M, )tex=370 nm, EX reso 
lution 8 nm, EM resolution 4 nm, Without EM polariZer, 
HV=830V). 
FIG. 3 is a study of the binding of 2 pM amounts of 
7-(1-Aminoethyl)camptothecin (7AEC) or 7-[N-(4-methyl 
1-piperaZino) aminomethyl]-(20S).-camptothecin (CT-17) 
(prepared in Example 18) to small unilamellar vesicles 
composed of electroneutral DMPC suspended in phosphate 
buffered saline. Experiments Were conducted at 37° C. using 
exciting light of 370 nm. Note that in the presence of 
increasing amounts of liposomes the drug anisotropy values 
increase until the majority of drug is liposome-bound. 
Analysis of the data reveals that the novel CT-17 agent has 
reduced membrane binding associations relative to the 
7AEC molecule (data analysis is carried out in FIG. 5). 
FIG. 4 is a study of the binding of 2 pM amounts of 
7-(1-Aminoethyl)camptothecin (7AEC) or 7-[N-(4-methyl 
1-piperaZino) aminomethyl]-(20S)—camptothecin (CT-17) 
to small unilamellar vesicles composed of negatively 
charged DMPG suspended in phosphate buffered saline. 
Experiments Were conducted at 37° C. using exciting light 
of 370 nm. Note that in the presence of increasing amounts 
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of liposomes the drug anisotropy values increase until the 
majority of drug is liposome-bound. Analysis of the data 
reveals that the novel CT-17 agent has reduced membrane 
binding associations for DMPG relative to the previously 
described 7AEC molecule (data analysis is carried out in 
FIG. 6). 
FIG. 5 shoWs double-reciprocal plots for the binding of 
7-(1-Aminoethyl)camptothecin (7AEC) or 7-[N-(4-methyl 
1-piperaZino) aminomethyl]-(20S)-camptothecin (CT-17) to 
small unilamellar vesicles composed of electroneutral 
DMPC suspended in phosphate buffered saline (PBS), pH 
7.4. Experiments Were conducted at 37° C. using exciting 
light of 370 nm. 
FIG. 6 shoWs double-reciprocal plots for the binding of 
7-(1-Aminoethy)camptothecin (7AEC) or 7-[N-(4-methyl 
1-piperaZino) aminomethyl]-(20S)-camptothecin (CT-17) to 
small unilamellar vesicles composed of negatively-charged 
DMPG suspended in phosphate buffered saline, pH 7.4. 
FIG. 7 is a graphical representation indicating the stabi 
liZation of the active lactone form of the drug CT-17 Within 
liposomal particles in phosphate buffered saline (PBS), 
plasma and Whole blood versus free drug in PBS. The 
liposomal particles studied in this experiment did not have 
a coating of polyethyleneglycol (PEG) on the surface of the 
particle as Was the case for the liposomal preparation 
characteriZed in FIG. 8. 
FIG. 8 is a graphical representation indicating the stabi 
liZation of the active lactone form of the drug CT-17 Within 
liposomal particles in phosphate buffered saline (PBS), 
plasma and Whole blood versus free drug in PBS. The 
liposomal particles studied in this experiment are long 
circulating or stealth liposomes containing a coating of 
polyethyleneglycol (PEG) on the surface of the particle. 
FIG. 9 is a typical phosphoimager picture shoWing the 
timecourse of the effects of various camptothecins on the 
relaxation of DNA in the presence of topoisomerase I. 
Topoisomerase I-mediated cleavage generates DNA frag 
ments that can be readily detected by electrophoresis and 
quantitated by phosphoimager analysis. Note that several of 
the analogs of the current invention such as 7-(1 
Guanidinopropyl)-20(S)camptothecin (lane#8) and 7-(1 
Guanadinoethyl)-20(S)camptothecin (lane#9) are good 
inducers of cleavable complex formation and the distribu 
tion of cleavage sites are comparable to those generated by 
camptothecin or 7-ethyl-10-hydroxycamptothecin (SN-38). 
FIG. 10 is a phosphoimager picture shoWing the dose 
response of various camptothecin drugs on the relaxation of 
DNA in the presence of topoisomerase I. Topoisomerase 
I-mediated cleavage generates DNA fragments that can be 
readily detected by electrophoresis and quantitated by phos 
phoimager analysis as shoWn. 
FIG. 11 contains a phosphoimager picture (bottom ?gure) 
shoWing the dose response effects of several of the novel 
polyamine camptothecin drugs of the current invention on 
the relaxation of DNA in the presence of topoisomerase I. 
Topoisomerase I-mediated cleavage generates DNA frag 
ments that can be readily detected by electrophoresis and 
quantitated by phosphoimager analysis (top ?gure). Note 
that several of the analogs of the current invention such as 
7-[N-(4-methyl-1-piperaZino) aminomethyl]-(20S) 
camptothecin (CT-1 7) are capable of inducing cleavable 
complex formation and the distribution of cleavage sites are 
comparable to those generated by camptothecin or 7-ethyl 
10-hydroxycamptothecin (SN-38). Quantitation shoWs that 
the intrinsic potency of the CT-17 analog is someWhat less 
than the potencies of the camptothecin and SN-38 standards. 
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However, CT-17 can be actively loaded and retained in 
liposomal particles (unlike camptothecin and SN-38), 
thereby allowing advanced liposome-based tumor targeting 
to be used to deliver very high concentrations of CT-17 
selectively to the tumor site. 
DETAILED DESCRIPTION OF THE 
INVENTION 
As previously described, the present invention relates to 
novel camptothecin and homocamptothecin analogs/drugs 
(hereinafter referred to as “compounds”) many of Which 
incorporate polyamine moieties. Unlike the monoamine 
derivatives such as 7AEC described in the prior art, the 
presence of polyamine substituents at the 7 position in the 
camptothecin compounds and the 12 position in the 
homocamptothecin compounds means that the compounds 
of the present invention are characteriZed by the spread of a 
positive charge over a greater surface area. This advanta 
geously results in compounds of increased Water-solubility 
Which also exhibit reduced membrane binding. 
Advantageously, compounds of the present invention and 
particularly those camptothecin analogs/derivatives With a 
polyamine substituent at the 7 position and those 
homocamptothecin compounds With a polyamine substitu 
ent at the 12 position display reduced membrane binding but 
are still capable of crossing membranes in response to a pH 
gradient. Accordingly, the compounds of the present inven 
tion may be readily actively loaded into liposomal particles 
such as the particles described in US. Pat. Nos. 5,316,771, 
5,552,156 and 5,736,156, the disclosures of Which are all 
fully incorporated herein by reference. Since DNA is highly 
negatively-charged, the Widespread positive charge of the 
polyamine bearing compounds of the present invention 
enhances interaction of those compounds With DNA. The 
resulting compound-DNA interaction functions to further 
stabiliZe the compound in its active lactone form as 
described by Yang et al. in PCT/US 98/20941. Further, the 
positively-charged polyamine functionalities of the present 
compounds discourages compound binding With blood pro 
teins such as albumin and this reduced blood protein binding 
promotes more efficient and effective antitumor activity 
against cancer cells. 
As an additional bene?t, the linking alkyl chain provided 
betWeen the nitrogen substituent and the pyridine ring may 
be lengthened or shortened to control the distance over 
Which the positive charge character is spread. Thus, the 
compounds of the present invention may be tailored to 
provide desired Water solubility, membrane interaction, 
DNA interaction and plasma protein interaction character 
istics to meet the particular needs and application of the 
compound in treating various types of cancer cells (eg. 
colon, lung, breast, malignant melanoma). 
The compounds of the present invention are generally 
prepared by substitution of the 7-position of camptothecins 
such as the parent drug camptothecin and the 12 position of 
homocamptothecins With Water-soluble aminoalkyl moieties 
resulting in a more Water-soluble drug. The aminoalkyl 
moieties may incorporate both unbranched and branch alkyl 
chains. To achieve this end the camptothecin/ 
homocamptothecin is suspended in organic solvents such as 
DMSO, DMF and CHCl3 or Water Where it is stirred and 
cooled to approximately —10—25° C. Halo alcohols, amino 
alcohols, amino aldehydes, halo aldehydes, halo ketones, 
aZido alcohols, aZido aldehydes, sulfuric acid, iron sulfate 
and oxidiZing reagents such as peracids and hydrogen per 
oxide are then added to the mixture. The mixture is stirred 
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to complete the reaction over a time frame of approximately 
4—24 hours at a temperature of approximately —10—25° C. 
Any precipitate that forms is removed by ?ltration and the 
product is isolated after removal of the solvent. Solvent 
removal may be completed by any appropriate means knoWn 
in art including rotary evaporator. 
Compounds of the present invention include those having 
the folloWing structures: 
Where Z is: 
A) C1_2O NRlR2 Where 
(1) R1 is hydrogen, C1_18 alkyl, C3_7 cycloalkyl, C3_7 
cycloalkyl-C1_18 alkyl, C2_18 alkenyl, hydroxy-C1_18 
alkyl, C1_18 alkoxy-C1_18 alkyl and R2 is C1_2O NR3R4 
Where (a) R3 and R4 are independently, hydrogen, C1_18 
alkyl, C3_7 cycloalkyl, C3_7 cycloalkyl-C1_18 alkyl, 
C2_18 alkenyl, hydroxy-C1_18 alkyl, CL18 alkoxy-C1_18 
alkyl, 3—7-membered heterocyclic ring Which may con 
tain a O, S or N group; (b) R3 is hydrogen and R4 is 
C1_18 alkyl, C3_7 cycloalkyl, C3_7 cycloalkyl-C1_18 
alkyl, C2_8 alkenyl, hydroxy-C1_18 alkyl or C1_18 
alkoxy-C1_18 alkyl, perhalo-C1_18 alkyl, C3_7 
cycloalkyl, C3_7 cycloalkyl-C1_18 alkyl, C2_18 alkenyl, 
hydroxy-C1_18 alkyl, C1_18 alkoxy, C1_18 alkoxy-C1_18 
alkyl; (c) R3 and R4 taken together With the nitrogen 
atom to Which they are attached form a saturated 
3—7-membered heterocyclic ring Which may contain a 
O, S or NR5 group, Where R5 is hydrogen, C1_6 alkyl, 
perhalo-C1_6 alkyl, aryl, aryl substituted With one or 
more groups selected from the group consisting of C1_6 
alkyl, halogen, nitro, amino, C1_6 alkyl, C1_6 alkoxy, 
C1_6 alkoxy-C1_6 alkyl and —COR6 Where R6 is 
hydrogen, C1_6 alkyl perhalo-C1_6 alkyl, C1_6 alkoxy, 
aryl, and aryl substituted With one or more C1_6 alkyl, 
perhalo-C1_6 alkyl, hydroxy-C1_6 alkyl, or C1_6 alkoxy 
C1_6 alkyl groups; 
(2) R1 is hydrogen, C3_18 alkyl, C3_7 cycloalkyl, C3_7 
cycloalkyl-C1_18 alkyl, C2_18 alkenyl, hydroxy-C1_18 
alkyl, C1_18 alkoxy-C1_18 alkyl, and R2 is one of the 
folloWing alkylamines or alkylpolyamines or a corre 
sponding salt form: 
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Camptothecin and homocamptothecin have an asymmet 
ric carbon atom at the ot-position and [3-position, 
respectively, and therefore exist in tWo enantiomeric forms, 
ie the (R) and (S) con?gurations. Other camptothecins and 
homocamptothecins also exist in tWo enantiomeric forms. 
This invention includes both enantiomeric forms of camp 
tothecins and homocamptothecins and all combinations of 
these forms, including racemic mixtures designated as (RS). 
The 7-modi?ed camptothecin and 12-modi?ed 
homocamptothecins compounds of the invention are admin 
istered in a dose Which is effective at inhibiting the enZyme 
topoisomerase I. These effective amounts are generally from 
about 1—80 mg/kg of body Weight per Week, preferably 
about 2—40 mg/kg per Week. The compounds of this inven 
tion may be administered in much higher doses than the 
corresponding parent compounds, because the compounds 
of the invention are anticipated to have substantially less 
toxicity than the parent compounds. This is likely because 
modi?cation at the C-7 position in camptothecins and C-12 
position in homocamptothecins promotes higher levels of 
lactone in the presence of albumin. Liposomal encapsulation 
also enhances the blood lactone levels of the polyamine 
compounds of the present invention. The polyamine com 
pounds display high retention in liposomal carriers dispersed 
in blood because of the reduced membrane interactions of 
the compounds, alloWing the agents to be better retained in 
the internal aqueous compartments of the particles. While 
not being bound by any particular scienti?c theory, it is 
believed that the loWer toxicity of the present compounds is 
due to the Water solubility and reduced membrane and 
albumin binding of the modi?ed compounds. In any event, 
the ot-hydroxyl of camptothecin analogs and [3-hydroxy of 
homocamptothecin analogs is thought to be required in 
underivatiZed form for camptothecin, homocamptothecin 
and analogs/derivatives to be optimally potent antileukemia 
and anti-tumor agents. This property of the present com 
pounds is surprisingly advantageous in optimiZing the mac 
romolecular interactions and drug delivery characteristics of 
the compounds for optimal use in therapy 
In addition, it is Well-knoWn that the lactone ring of 
camptothecin, homocamptothecin and their analogs/ 
derivatives opens to a physiologically inactive open form at 
physiological pH, 7.2, (J. Fassberg and V. J. Stella, J. Pharm. 
Sci. (1992) 81: 676—684; T. G. Burke, A. K. Mishra, M. C. 
Wani, and M. E. Wall, Biochem., 32(20), 5352 (1993)). The 
compounds of the present invention may be administered as 
a pharmaceutical composition containing the compounds 
and a pharmaceutically acceptable carrier or diluent. The 
compounds can be administered as their ring open salt 
forms, since relactoniZation to their active forms can occur 
in the body (especially at sites of reduced pH). The active 
material can also be mixed With other active materials Which 
do not impair the desired action and/or supplement the 
desired action. The active materials according to the present 
invention can be administered by any route, for example, 
orally, nasally, parenterally, intravenously, intradermally, 
subcutaneously, or topically, in liquid or solid form. 
For the purposes of parenteral therapeutic administration, 
the active ingredient may be incorporated into a solution or 
suspension. The solutions or suspensions may also include 
the folloWing components: a sterile diluent such as Water:for 
injection, suspensions of liposomal particles Whereby the 
particles contain stable, active drug Within the core of the 
particle in a pH controlled and protected environment or 
associated to the outside of the particle or any of the bilayers 
of the particle, saline solution, ?xed oils, polyethylene 
glycols, glycerine, propylene glycol or other synthetic sol 
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vents; antibacterial agents such as benZyl alcohol or methyl 
parabens; antioxidants such as ascorbic acid or sodium 
bisul?te; chelating agents such as ethylenediaminetetraace 
tic acid; buffers such as acetates, citrates or phosphates and 
agents for the adjustment of tonicity such as sodium chloride 
or dextrose. The parenteral preparation can be enclosed in 
ampoules, disposable syringes or multiple dose vials made 
of glass or plastic. 
Another mode of administration of the compounds of this 
invention is oral. Oral compositions Will generally include 
an inert diluent or an edible carrier. They may be enclosed 
in gelatin capsules or compressed into tablet. For the pur 
pose of oral therapeutic administration, the aforesaid com 
pounds may be incorporated With excipients and used in the 
form of tablets, troches, capsules, elixirs, suspensions, 
syrups, Wafers, cheWing gums and the like. 
The tablets, pills, capsules and the like may contain the 
folloWing ingredients: a binder such as microcrystalline 
cellulose, gum tragacanth or gelatin; an excipient such as 
starch or lactose, a disintegrating agent such as alginic acid, 
Primogel, corn starch and the like; a lubricant such as 
magnesium stearate or Sterotes; a glidant such a colloidal 
silicon dioxide; and a sWeetening agent such as sucrose or 
saccharin or ?avoring agent such as peppermint, methyl 
salicylate, or orange ?avoring may be added. When the 
dosage unit is in the form of a capsule, it may contain, in 
addition to material of the above type, a liquid carrier such 
as a fatty oil. Other dosage unit forms may contain other 
various materials Which modify the physical form of the 
dosage unit, for example, as coatings. Thus tablets or pills 
may be coated With sugar, shellac, or other enteric coating 
agents. A syrup may contain, in addition to the active 
compounds, sucrose as a sWeetening agent and certain 
preservatives, dyes and coloring and ?avors. Materials used 
in preparing these various compositions should be pharma 
ceutically or veterinarally pure and non-toxic in the amount 
used. 
The folloWing synthesis and examples are presented to 
further illustrate the present invention, but is not to be 
considered as limited thereto. In the examples, NMR spectra 
Were obtained using a Varian VXR 300 MHZ Instrument and 
mass spectra Were obtained using an Ion Spec Mass Spec 
trometer. 
EXAMPLE 1 
7-Chloromethylcamptothecin (Chem. Pharm. Bull. 1991, 
39, 2574): 
To a suspension of camptothecin (3.00 g, 8.6 mmol) in a 
mixture of chloroacetaldehyde (18 ml) and H20 (75 ml), 
75% H2SO4 (75 ml) Was added dropWise, and then 
FeSO47H2O (2.40 g, 8.6 mmol) Was added. To the ice-cold 
mixture, 30% H2O2 (15 ml, 6.6 mmol) Was added dropWise 
for 2 h With stirring. The mixture Was stirred at room 
temperature for 14 h and then diluted With H2O, extracted 
With chloroform (3><200 ml), and the organic layer Was 
Washed With brine and dried over MgSO4. Evaporation of 
the solvent gave a broWn oil Which Was puri?ed using 
column chromatography (eluent: chloroform: methanol 
98:2). The product Was isolated as a yelloW solid. 
7-Chloromethylcamptothecin (3.0 g, 88% yield) Was yielded 
in the form of pale yelloW prisms. Melting point (MP) 
261—262° C., IR (K Br) v: 1770, 1665, 1605 cm_1. 1H-NMR 
(DMSO-d?) 6: 0.89 (3H, t, J=7 HZ), 1.88 (2H, q, J=7 HZ), 
4.27 (2H, s, 7-CH2Cl), 5.40 (2H, s, C5—H2), 5.80 (2H, s, 
C17—H2), 6.50 (1H, s, 20-OH), 7.33 (1H, s, C14—H), 
7.60—8.21 (4H, m, arom).Ms m/Z: 396 (M+). Anal. Calcd for 
C21H17ClN2O4 (396.83): C, 63.56: H, 4.32: N, 7.06. Found: 
C, 63.32; H, 4.60; N, 7.27. 
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EXAMPLE 2 
7-(1-Chloropropyl)camptothecin: 
To a suspension of camptothecin (3.00 g, 8.6 mmol) in a 
mixture of 4-chlorobutanal (3 g, 30 mmol) and H20 (75 ml). 
75% HZSO4 (75 ml) Was added dropWise, and then 
FeSO47H2O (2.40 g, 8.6 mmol) Was added. To the ice-cold 
mixture, 30% H2O2 (15 ml, 6.6 mmol) Was added dropWise 
for 2 h With stirring. The mixture Was stirred at room 
temperature for 14 h then diluted With H2O, extracted With 
chloroform (3><200 ml), and the organic layer Was Washed 
With brine and dried over MgSO4. Evaporation of the 
solvent gave a broWn oil Which Was puri?ed using column 
chromatography (eluent: chloroform: methanol 98:2). The 
product Was isolated as a yelloW solid. The yield of 7-(1 
chloropropyl)camptothecin Was 3.1 g (85% yield, yelloW 
solid). MP 215—216° C. IR (K Br) v: 1760, 1660, 1605 cm_1. 
1H-NMR (DMSO-d?) 6: 0.89 (3H, t, J=7 HZ), 1.88 (2H, q, 
J=7 HZ), 2.22—2.29 (m, 2H, CH2), 3.37 (m, 2H, CH2), 4.41 
(2H, m, 7-CH2Cl), 5.40 (2H, s, C5—H2), 5.80 (2H, S, 
C17—H2), 6.50 (1H, s, 20-OH), 7.33 (1H, s, C14—H), 
7.60—8.21 (4H, m, arom).Ms m/Z: 424 (M+). Anal. Calcd for 
C23H21ClN2O4 (424.88): C, 65.02: H, 4.98: N, 6.59. Found: 
C, 65.33; H, 4.60; N, 6.27. 
EXAMPLE 3 
7-(1-Chloropentyl)camptothecin: 
To a suspension of camptothecin (3.00 g, 8.6 mmol) in a 
mixture of 6-chlorohexanal (6.9 g, 50 mmol) and H20 (75 
ml), 75% HZSO4 (75 ml) Was added dropWise, and then 
FeSO47H2O (2.40 g, 8.6 mmol) Was added. To the ice-cold 
mixture, 30% H2O2 (15 ml, 6.6 mmol) Was added dropWise 
for 2 h With stirring. The mixture Was stirred at room 
temperature for 14 h and then diluted With H20, and 
extracted With chloroform (3x200 ml). The organic layer 
Was Washed With brine and dried over MgSO4. Evaporation 
of the solvent gave a broWn oil Which Was puri?ed using 
column chromatography (eluent: chloroform: methanol 
98:2). The product Was isolated as a yelloW solid. The yield 
of 7-(1-chloropenthyl)camptothecin Was (3.98 g, 88% yield, 
yelloW solid). MP 254—255° C. IR (K Br) v: 1770, 1665, 
1605 cm_1. 1H-NMR (DMSO-d6) 6: 0.89 (3H, t, J=7 HZ), 
1.15—2.31(m, 10H, 5CH2), 3.23 (m, 2H, CH2), 4.41(m, 2H, 
7-CH2Cl), 5.40 (2H, S, C5—H2), 5.80 (2H, S, C17—H2), 
6.50 (1H, s, 20-OH), 7.33 (1H, S, C14—H), 7.60—8.21 (4H, 
m, arom).Ms m/Z: 452 (M+). Anal. Calcd for CZSHZSCINZO4 
(452.94): C, 66.03: H, 5.56: N, 6.18. Found: C, 66.33; H, 
5.62; N, 6.27. 
EXAMPLE 4 
7-(1-AZidoethyl)camptothecin: 
To a suspension of camptothecin (3.00 g, 8.6 mmol) in a 
mixture of 3-aZidopropanal (4.9 g, 50 mmol) and H20 (75 
ml), 75% HZSO4 (75 ml) Was added dropWise. and then 
FeSO47H2O (2.40 g, 8.6 mmol) Was added. To the ice-cold 
mixture, 30% H2O2 (15 ml, 6.6 mmol) Was added dropWise 
for 2 h With stirring. The mixture Was stirred at room 
temperature for 14 h then diluted With H2O, extracted With 
chloroform (3><200 ml), and the organic layer Was Washed 
With brine and dried over MgSO4. Evaporation of the 
solvent gave a broWn oil Which Was puri?ed using column 
chromatography (eluent: chloroform: methanol 98:2). The 
product Was isolated as yelloW solid. The yield of 7-(1 
aZidoethyl)camptothecin Was 2.94 g (82% yield, yelloW 
solid). MP 193—194° C. IR (K Br) v: 2020, 1770, 1665, 1605 
cm_1. 1H NMR (CDCl3) 6 8.28 (1H, d, J 7.3 Hz), 8.07 (1H, 
d, J 7.4 HZ), 7.84 (1H, m), 7.75—7.67 (2H, m), 5.77 (1 h, d, 
J 16.4 HZ), 5.37—5.28 (3H, m), 3.84 (2H, t, J 6.6 HZ), 3.43 
(2H, t, J 7.0 HZ), 1.93—1.84 (2H, m), 1.05 (3H, t, 7.4 HZ).Ms 
10 
15 
20 
25 
30 
35 
40 
45 
50 
55 
60 
65 
16 
m/Z: 452 (M+). Anal. Calcd for C22H19N5O4 (417.42): C, 
63.30: H, 4.59: N, 16.78. Found: C, 63.53; H, 4.62; N, 16.07. 
High resolution mass spectrometry (HRMS) M+: calcd. for 
C22H19N5O4: 417.1437; found: 417.1438. 
EXAMPLE 5 
7-(1-AZidopropyl)camptothecin: 
To a suspension of camptothecin (3.00 g, 8.6 mmol) in a 
mixture of 4-aZidobutanal (5.51 g, 50 mmol) and H20 (75 
ml), 75% HZSO4 (75 ml) Was added dropWise, and then 
FeSO47H2O (2.40 g, 8.6 mmol) Was added. To the ice-cold 
mixture, 30% H2O2 (15 ml, 6.6 mmol) Was added dropWise 
for 2 h With stirring. The mixture Was stirred at room 
temperature for 14 h and then diluted With H2O, extracted 
With chloroform (3><200 ml), and the organic layer Was 
Washed With brine and dried over MgSO4. Evaporation of 
the solvent gave a broWn oil Which Was puri?ed using 
column chromatography (eluent: chloroform: methanol 
98:2). The product Was isolated as a broWn solid. The yield 
of 7-(l -aZidopropyl)camptothecin Was: 3.15 g, 85% yield, 
yelloW solid. MP 209—210° C. IR (K Br) v: 2020, 1770, 
1660, 1605 cm_1. 1H NMR (CDCl3) 6 8.22 (1H, d, J 8.5 HZ), 
8.08 (1H, d, J 8.4 HZ), 7.79 (1H, m), 7.68—7.63 (2H, m), 5.74 
(1H, d, J 16.4 HZ), 5.33—5.26 (3H, m), 3.46 (2H, 6.2 HZ), 
3.26 (1H, 7.4 HZ), 2.08—1.84 (4H, m), 1.02 (3H, t, J 6.5 
HZ).Ms m/Z: 431 (M+). Anal. Calcd for C23H21N5O4 
(431.35): C, 64.03: H, 4.91: N, 16.23. Found: C, 64.33; H, 
4.62; N, 16.31. HRMS of M+calcd. For C23H21N5O4: 
431.1593. Found: 431.1595. 
EXAMPLE 6 
7-(1-AZidobutyl)camptothecin: 
To a suspension of camptothecin (3.00 g, 8.6 mmol) in a 
mixture of 5-aZidopentanal (6.3 g, 50 mmol) and H20 (75 
ml), 75% HZSO4 (75 ml) Was added dropWise, and then 
FeSO47H2O (2.40 g, 8.6 mmol) Was added. To the ice-cold 
mixture, 30% H2O2 (15 ml, 6.6 mmol) Was added dropWise 
for 2 h With stirring. The mixture Was stirred at room 
temperature for 14 h and then diluted With H2O, extracted 
With chloroform (3><200 ml), organic layer Was Washed With 
brine and dried over MgSO4. Evaporation of the solvent 
gave a broWn oil Which Was puri?ed using column chroma 
tography (eluent: chloroform: methanol 98:2). The product 
Was isolated as a broWn solid. Yield of 7-(1-aZidopropyl) 
camptothecin: 3.28 g, 82% yield, yelloW solid. MP 
227—228° C. IR (K Br) v: 2020, 1765, 1660, 1610 cm_1. 1H 
NMR (CDCl3) 6 8.24 (1H, d, J 8.5 HZ), 8.09 (1H, d, J 8.7 
HZ), 7.77 (1H, m), 7.72—7.68 (1H, m), 5.76 (1H, d, J 8.2 HZ), 
5.35—5.27 (3H, m), 3.63 (2H, d, J 6.0HZ), 3.26 (1H, 7.7 HZ), 
1.93—1.78 (6H, m), 1.04 (3H, t, J 7.3 HZ).Ms m/Z: 445 (M+). 
Anal. Calcd for C24H23N5O4 (445.48): C, 64.71: H, 5.2: N, 
15.72. Found: C, 64.43; H, 5.38; N, 15.41. HRMS of M+for 
C24H23N5O4: calculated: 445.1750; Found: 445.1752. 
EXAMPLE 7 
7-(1-AZidopentyl)camptothecin: 
To a suspension of camptothecin (3.00 g, 8.6 mmol) in a 
mixture of 6-aZidohexanal (7.05 g, 50 mmol) and H20 (75 
ml). 75% HZSO4 (75 ml) Was added dropWise, and then 
FeSO47H2O (2.40 g, 8.6 mmol) Was added. To the ice-cold 
mixture, 30% H2O2 (15 ml, 6.6 mmol) Was added dropWise 
for 2 h With stirring. The mixture Was stirred at room 
temperature for 14 h then diluted With H2O, extracted With 
chloroform (3><200 ml), and the organic layer Was Washed 
With brine and dried over MgSO4. Evaporation of the 
solvent gave a broWn oil Which Was puri?ed using column 
chromatography (eluent: chloroform: methanol 98:2). The 
product Was isolated as a broWn solid. Yield of 7-(1 

















